IRES-dependent translation of egr2 is induced under inflammatory conditions

RNA

Volumn 18, Issue 10, 2012, Pages 1910-1920

  Rübsamen, Daniela ^a   Blees, Johanna S ^a   Schulz, Kathrin ^a   Döring, Claudia ^a   Hansmann, Martin Leo ^a   Heide, Heinrich ^a   Weigert, Andreas ^a   Schmid, Tobias ^a   Brüne, Bernhard ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Egr2; Il 1 ; Inflammation; IRES; P38 MAPK; Translation

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 2; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; INTERNAL RIBOSOME ENTRY SITE; MACROPHAGE; MICROARRAY ANALYSIS; POLYSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; EARLY GROWTH RESPONSE PROTEIN 2; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; PROTEIN BIOSYNTHESIS; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RIBOSOMES; U937 CELLS; UP-REGULATION;

EID: 84866629402     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.033019.112     Document Type: Article

References (44)

1. Averous J, Fonseca BD, Proud CG. 2008. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27: 1106-1113.
2. Bonnal S, Pileur F, Orsini C, Parker F, Pujol F, Prats AC, Vagner S. 2005. Heterogeneous nuclear ribonucleoprotein A1 is a novel internal ribosome entry site trans-acting factor that modulates alternative initiation of translation of the fibroblast growth factor 2 mRNA. J Biol Chem 280: 4144-4153.
3. Bradley EW, Ruan MM, Oursler MJ. 2008. Novel pro-survival functions of the Kruppel-like transcription factor Egr2 in promotion of macrophage colony-stimulating factor-mediated osteoclast survival downstream of the MEK/ERK pathway. J Biol Chem 283: 8055-8064.
4. Cloninger C, Bernath A, Bashir T, Holmes B, Artinian N, Ruegg T, Anderson L, Masri J, Lichtenstein A, Gera J. 2011. Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther 10: 2244-2256.
5. Cobbold LC, Wilson LA, Sawicka K, King HA, Kondrashov AV, Spriggs KA, Bushell M, Willis AE. 2010. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1. Oncogene 29: 2884-2891.
6. Coldwell MJ, Mitchell SA, Stoneley M, MacFarlane M, Willis AE. 2000. Initiation of Apaf-1 translation by internal ribosome entry. Oncogene 19: 899-905.
7. Dhamija S, Doerrie A, Winzen R, Dittrich-Breiholz O, Taghipour A, Kuehne N, Kracht M, Holtmann H. 2010. IL-1-induced post-transcriptional mechanisms target overlapping translational silencing and destabilizing elements in IκBζ mRNA. J Biol Chem 285: 29165-29178.
8. Faivre S, Kroemer G, Raymond E. 2006. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
9. Fang F, Ooka K, Bhattacharyya S, Wei J, Wu M, Du P, Lin S, Del Galdo F, Feghali-Bostwick CA, Varga J. 2011. The early growth response gene Egr2 (alias Krox20) is a novel transcriptional target of transforming growth factor-β that is up-regulated in systemic sclerosis and mediates profibrotic responses. Am J Pathol 178: 2077-2090.
10. Garcia-Gutierrez P, Juarez-Vicente F, Gallardo-Chamizo F, Charnay P, Garcia-Dominguez M. 2011. The transcription factor Krox20 is an E3 ligase that sumoylates its Nab coregulators. EMBO Rep 12: 1018-1023.
11. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. 2004. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi: 10.1186/gb-2004-5-10-r80.
12. Guertin DA, Sabatini DM. 2007. Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
13. Holcik M. 2004. Targeting translation for treatment of cancer - a novel role for IRES? Curr Cancer Drug Targets 4: 299-311.
14. Ichijo H. 1999. From receptors to stress-activated MAP kinases. Oncogene 18: 6087-6093.
15. Joseph LJ, Le Beau MM, Jamieson GA Jr, Acharya S, Shows TB, Rowley JD, Sukhatme VP. 1988. Molecular cloning, sequencing, and mapping of EGR2, a human early growth response gene encoding a protein with "zinc-binding finger" structure. Proc Natl Acad Sci 85: 7164-7168.
16. Lang KJ, Kappel A, Goodall GJ. 2002. Hypoxia-inducible factor-1αmRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13: 1792-1801.
17. Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y. 2001. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 61: 3741-3749.
18. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. 2001. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 30: 355-368.
19. Papadopoulou C, Patrinou-Georgoula M, Guialis A. 2010. Extensive association of HuR with hnRNP proteins within immunoselected hnRNP and mRNP complexes. Biochim Biophys Acta 1804: 692-703.
20. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC Jr, Sonenberg N. 1994. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371: 762-767.
21. Pickering BM, Willis AE. 2005. The implications of structured 5′untranslated regions on translation and disease. Semin Cell Dev Biol 16: 39-47.
22. Pospisil V, Vargova K, Kokavec J, Rybarova J, Savvulidi F, Jonasova A, Necas E, Zavadil J, Laslo P, Stopka T. 2011. Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage differentiation. EMBO J 30: 4450-4464.
23. Proud CG. 2004. Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol 279: 215-244.
24. Proud CG. 2006. Regulation of protein synthesis by insulin. Biochem Soc Trans 34: 213-216.
25. R Development Core Team. 2005. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
26. Safford M, Collins S, Lutz MA, Allen A, Huang CT, Kowalski J, Blackford A, Horton MR, Drake C, Schwartz RH, et al. 2005. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6: 472-480.
27. Sawicka K, Bushell M, Spriggs KA, Willis AE. 2008. Polypyrimidine-tract- binding protein: A multifunctional RNA-binding protein. Biochem Soc Trans 36: 641-647.
28. Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, Rübsamen D, Schulz K, Weigert A, Baker AR, Colburn NH, et al. 2011. Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis 32: 1427-1433.
29. Sherrill KW, Byrd MP, Van Eden ME, Lloyd RE. 2004. BCL-2 translation is mediated via internal ribosome entry during cell stress. J Biol Chem 279: 29066-29074.
30. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. 2005. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway. J Biol Chem 280: 10964-10973.
31. Shi Y, Frost PJ, Hoang BQ, Benavides A, Sharma S, Gera JF, Lichtenstein AK. 2008. IL-6-induced stimulation of c-myc translation in multiple myeloma cells is mediated by myc internal ribosome entry site function and the RNA-binding protein, hnRNP A1. Cancer Res 68: 10215-10222.
32. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. 2011. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: Critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem 286: 67-78.
33. Silvera D, Formenti SC, Schneider RJ. 2010. Translational control in cancer. Nat Rev Cancer 10: 254-266.
34. Sonenberg N, Hinnebusch AG. 2007. New modes of translational control in development, behavior, and disease. Mol Cell 28: 721-729.
35. Sonenberg N, Hinnebusch AG. 2009. Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 136: 731-745.
36. Spriggs KA, Bushell M, Mitchell SA, Willis AE. 2005. Internal ribosome entry segment-mediated translation during apoptosis: The role of IRES-trans-acting factors. Cell Death Differ 12: 585-591.
37. Spriggs KA, Cobbold LC, Ridley SH, Coldwell M, Bottley A, Bushell M, Willis AE, Siddle K. 2009. The human insulin receptor mRNA contains a functional internal ribosome entry segment. Nucleic Acids Res 37: 5881-5893.
38. Vagner S, Galy B, Pyronnet S. 2001. Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2: 893-898.
39. Wek RC, Jiang HY, Anthony TG. 2006. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34: 7-11.
40. Yang L, Gu L, Li Z, Zhou M. 2010. Translation of TRAF1 is regulated by IRES-dependent mechanism and stimulated by vincristine. Nucleic Acids Res 38: 4503-4513.
41. Yasuda M, Schmid T, Rübsamen D, Colburn NH, Irie K, Murakami A. 2010. Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 49: 837-848.
42. Yeh CH, Hung LY, Hsu C, Le SY, Lee PT, Liao WL, Lin YT, Chang WC, Tseng JT. 2008. RNA-binding protein HuR interacts with thrombomodulin 5′ untranslated region and represses internal ribosome entry site-mediated translation under IL-1 β treatment. Mol Biol Cell 19: 3812-3822.
43. Yokota I, Sasaki Y, Kashima L, Idogawa M, Tokino T. 2010. Identification and characterization of early growth response 2, a zinc-finger transcription factor, as a p53-regulated proapoptotic gene. Int J Oncol 37: 1407-1416.
44. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31: 3406-3415.